The trajectory of companies tied to the drug's past presents a challenging investment picture . While the initial surge generated substantial profits , generic copies have significantly eroded market share . Investing in associated pharmaceutical firms now requires a thorough assessment of intellectual property rights , evolving healthcare changes,